Form: 8-K

Current report filing

April 27, 2017

Exhibit 99.1

 

LOGO  

 

Contacts:   
For Investors    For News Media
Agnes Lee    Alison Graves
O: 858-836-5971    O: 858-836-6789
investorrelations@resmed.com    news@resmed.com

ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2017

Revenue increased 13% to $514.2 million; up 14% on a constant currency basis

GAAP diluted earnings per share of $0.62; non-GAAP diluted earnings per share of $0.71

Operating cash flow of $67.6 million in the third quarter

SAN DIEGO, April 27, 2017 – ResMed Inc. (NYSE: RMD) today announced results for its quarter ended March 31, 2017. Revenue for the quarter was $514.2 million, a 13 percent increase compared to the same period of the prior year. Excluding the contribution from the Brightree business acquired in April 2016, revenue for the quarter was $479.2 million, a 6 percent increase.

“We had solid double-digit constant currency revenue growth in Q3, led by our Brightree software solutions as well as mask and device sales,” said Mick Farrell, ResMed’s chief executive officer. “This quarter we saw strong demand for our new AirFit 20 range of masks. We also made significant progress on software innovation with the launch of enhanced integration capabilities with Brightree and our AirSolutions cloud-based software platform. In our current quarter, we are launching our latest market-leading innovation: the ResMed AirMini – the world’s smallest CPAP.”

Farrell concluded, “Our focus on changing 20 million lives by 2020 has driven a pipeline of new products and connected care solutions that improve patient outcomes, create efficiencies for our homecare customers, and help physicians and providers better manage chronic disease while lowering healthcare costs.”

Analysis of third quarter results

Third quarter revenue in the Americas was $332.1 million, an 18 percent increase over the same period of the prior year. This included Brightree revenue of $35.0 million. Excluding Brightree, revenue in the Americas was $297.1 million, a 5 percent increase over the prior year. Revenue in combined EMEA and APAC was $182.1 million, an increase of 9 percent on a constant currency basis, compared to the same period of the prior year.

Gross margin in the third quarter was 58.3 percent, higher than the prior year’s quarter gross margin of 57.3 percent. The improvement in gross margin compared to prior year’s quarter was due to manufacturing and procurement efficiencies and an incremental contribution from the Brightree acquisition.


Income from operations for the quarter was $107.4 million, a 3 percent increase compared with the quarter ended March 31, 2016. Non-GAAP income from operations for the quarter was $126.7 million, a 13 percent increase compared to the same period of the prior year.

Selling, general and administrative expenses were $137.9 million, a 16 percent increase over the same period in the prior year, also a 16 percent increase on a constant currency basis. SG&A expenses increased to 26.8 percent of revenue in the quarter, compared with 26.3 percent reported in the quarter ended March 31, 2016.    

Research and development expenses were $35.1 million, or 6.8 percent of revenue. R&D expenses increased by 25 percent compared with the same period last year, or a 21 percent increase on a constant currency basis.

Amortization of acquired intangible assets was $11.4 million during the quarter, an increase of $6.8 million compared with the same period last year. The increase in amortization of acquired intangible assets was primarily due to the amortization expense associated with the Brightree acquisition. Stock-based compensation costs incurred during the quarter of $11.5 million consisted of expenses associated with employee equity grants, and our employee stock purchase plan.

Net income for the quarter was $87.8 million, a 3 percent decrease compared to the same period of the prior year. Non-GAAP net income was $100.7 million, a 3 percent increase compared to the prior year.

Non-GAAP measures adjust for amortization of acquired intangibles, acquisition related expenses and restructuring expenses.

GAAP diluted earnings per share for the quarter decreased 3 percent to $0.62. Non-GAAP diluted earnings per share of $0.71 were 3 percent higher compared with the same period of the prior year.

Cash flow from operations for the quarter was $67.6 million compared to net income in the current quarter of $87.8 million.

Dividend program

The ResMed board of directors today declared a quarterly cash dividend of $0.33 per share. The dividend will have a record date of May 11, 2017, payable on June 15, 2017. The dividend will be paid in U.S. currency to holders of ResMed’s common stock trading on the New York Stock Exchange. Holders of Chess Depositary Instruments trading on the Australian Securities Exchange will receive an equivalent amount in Australian currency, based on the exchange rate on the record date, and reflecting the 10:1 ratio between CDIs and NYSE shares. The ex-dividend date will be May 10, 2017 for common stock holders and for CDI holders. ResMed has received a waiver from the ASX’s settlement operating rules, which will allow ResMed to defer processing conversions between its common stock and CDI registers from May 10, 2017 through May 11, 2017 inclusive.

Webcast details

ResMed will discuss its financial and business results and outlook on its webcast at 1:30 p.m. U.S. Pacific Time today. The live webcast of the call can be accessed on ResMed’s Investor Relations website at investor.resmed.com. Please go to this section of the website and click on the icon for the “Q3 2017 earnings webcast” to register and listen to the live webcast. The online archive of the broadcast will be available on ResMed’s website after the live call. In addition, a telephone replay of the conference call will be available approximately two hours after the call by dialing 800-585-8367 (U.S.) and +1 416-621-4642 (international) and entering a passcode of 98293201. The telephone replay will be available until May 11, 2017.


About ResMed

ResMed (NYSE:RMD) changes lives with award-winning medical devices and cutting-edge cloud-based software applications that better diagnose, treat and manage sleep apnea, chronic obstructive pulmonary disease (COPD) and other chronic diseases. ResMed is a global leader in connected care, with more than 3 million patients remotely monitored every day. Our 5,000-strong team is committed to creating the world’s best tech-driven medical device company – improving quality of life, reducing the impact of chronic disease, and saving healthcare costs in more than 100 countries.

Safe harbor statement

Statements contained in this release that are not historical facts are “forward-looking” statements as contemplated by the Private Securities Litigation Reform Act of 1995. These forward-looking statements – including statements regarding ResMed’s projections of future revenue or earnings, expenses, new product development, new product launches and new markets for its products and the integration of acquisitions – are subject to risks and uncertainties, which could cause actual results to materially differ from those projected or implied in the forward-looking statements. Additional risks and uncertainties are discussed in ResMed’s periodic reports on file with the U.S. Securities & Exchange Commission. ResMed does not undertake to update its forward-looking statements.

- More -


RESMED INC AND SUBSIDIARIES

Condensed Consolidated Statements of Income (Unaudited)

(In thousands, except per share data)

 

     Three Months Ended
March 31,
    Nine Months Ended
March 31,
 
     2017     2016     2017     2016  

Net revenue

   $ 514,204     $ 453,879     $ 1,510,051     $ 1,320,066  

Cost of sales

     214,490       193,999       627,012       557,460  

Astral field safety notification expenses (1)

     —         —         5,070       —    

SERVE-HF accrual release (1)

     —         —         —         (2,402
  

 

 

   

 

 

   

 

 

   

 

 

 

Gross profit

     299,714       259,880       877,969       765,008  
  

 

 

   

 

 

   

 

 

   

 

 

 

Operating expenses:

        

Selling, general and administrative

     137,864       119,351       406,028       348,664  

Research and development

     35,130       28,109       107,761       84,271  

Restructuring expenses (1)

     7,945       —         12,358       6,914  

Litigation settlement expenses (1)

     —         —         8,500       —    

Acquisition related expenses (1)

     —         3,550       10,076       3,550  

Amortization of acquired intangible assets (1)

     11,378       4,558       34,809       11,294  
  

 

 

   

 

 

   

 

 

   

 

 

 

Total operating expenses

     192,317       155,568       579,532       454,693  
  

 

 

   

 

 

   

 

 

   

 

 

 

Income from operations (1)

     107,397       104,312       298,437       310,315  
  

 

 

   

 

 

   

 

 

   

 

 

 

Other income (expenses), net:

        

Interest income (expense), net

     (2,911     2,131       (7,841     8,028  

Other, net

     3,504       2,553       6,525       3,791  
  

 

 

   

 

 

   

 

 

   

 

 

 

Total other income (expenses), net

     593       4,684       (1,316     11,819  
  

 

 

   

 

 

   

 

 

   

 

 

 

Income before income taxes

     107,990       108,996       297,121       322,134  
  

 

 

   

 

 

   

 

 

   

 

 

 

Income taxes excluding ASU 2016-09 (2)

     21,601       20,538       60,336       62,757  

Income taxes relating to ASU 2016-09 (2)

     (1,434     (2,333     (3,887     (9,906
  

 

 

   

 

 

   

 

 

   

 

 

 

Total income taxes

     20,167       18,205       56,449       52,851  
  

 

 

   

 

 

   

 

 

   

 

 

 

Net income (1)

   $ 87,823     $ 90,791     $ 240,672     $ 269,283  
  

 

 

   

 

 

   

 

 

   

 

 

 

Basic earnings per share (2)

   $ 0.62     $ 0.65     $ 1.70     $ 1.92  

Diluted earnings per share (2)

   $ 0.62     $ 0.64     $ 1.69     $ 1.90  

Non-GAAP diluted earnings per share (1) (2)

   $ 0.71     $ 0.69     $ 2.05     $ 2.01  

Basic shares outstanding

     141,714       140,187       141,266       140,140  

Diluted shares outstanding (2)

     142,724       141,232       142,363       141,666  

 

(1) See the reconciliation of non-GAAP financial measures in the table at the end of the press release.
(2) As a result of the adoption of ASU 2016-09 “Improvements to Employee Share-Based Payment Accounting” during the quarter ended June 30, 2016 we now recognize an income tax impact relating to share-based payment transactions. The income taxes for the three and nine months ended March 31, 2016 have been restated to reflect the adoption of the standard as the benefit was previously recorded as a reduction to Additional Capital.

- More -


RESMED INC AND SUBSIDIARIES

Condensed Consolidated Balance Sheets (Unaudited – In thousands)

 

     March 31,
2017
    June 30,
2016
 

ASSETS:

    

Current assets:

    

Cash and cash equivalents

   $ 827,310     $ 731,434  

Accounts receivable, net

     413,612       382,086  

Inventories

     259,870       224,456  

Prepayments and other current assets

     104,569       81,743  
  

 

 

   

 

 

 

Total current assets

     1,605,361       1,419,719  
  

 

 

   

 

 

 

Property, plant and equipment, net

     387,412       384,276  

Goodwill

     1,050,083       1,059,245  

Other intangibles, net

     267,404       299,808  

Deferred income taxes and other non-current assets

     112,303       93,657  
  

 

 

   

 

 

 

Total non-current assets

     1,817,202       1,836,986  
  

 

 

   

 

 

 

Total assets

   $ 3,422,563     $ 3,256,705  
  

 

 

   

 

 

 

LIABILITIES AND STOCKHOLDERS’ EQUITY:

    

Current liabilities:

    

Accounts payable

   $ 82,846     $ 92,571  

Accrued expenses

     169,896       156,805  

Deferred revenue

     48,682       50,009  

Income taxes payable

     34,854       39,166  

Short-term debt

     —         299,438  
  

 

 

   

 

 

 

Total current liabilities

     336,278       637,989  
  

 

 

   

 

 

 

Non-current liabilities:

    

Deferred income taxes

     12,988       9,061  

Deferred revenue

     49,135       40,281  

Other long-term liabilities

     856       1,211  

Long-term debt

     1,168,350       873,332  
  

 

 

   

 

 

 

Total non-current liabilities

     1,231,329       923,885  
  

 

 

   

 

 

 

Total liabilities

     1,567,607       1,561,874  
  

 

 

   

 

 

 

STOCKHOLDERS’ EQUITY:

    

Common stock

     567       563  

Additional paid-in capital

     1,352,676       1,303,238  

Retained earnings

     2,261,425       2,160,299  

Treasury stock

     (1,546,612     (1,546,611

Accumulated other comprehensive income

     (213,100     (222,658
  

 

 

   

 

 

 

Total stockholders’ equity

   $ 1,854,956     $ 1,694,831  
  

 

 

   

 

 

 

Total liabilities and stockholders’ equity

   $ 3,422,563     $ 3,256,705  
  

 

 

   

 

 

 

- More -


RESMED INC AND SUBSIDIARIES

Condensed Consolidated Statements of Cash Flows (Unaudited – In thousands)

 

     Nine Months Ended
March 31,
 
     2017     2016  

Cash flows from operating activities:

    

Net income

   $ 240,672     $ 269,283  

Adjustment to reconcile net income to cash provided by operating activities:

    

Depreciation and amortization

     83,989       59,827  

Impairment of long-lived assets

     —         2,815  

Stock-based compensation costs

     34,263       34,779  

Changes in fair value of business combination contingent consideration

     10,076       (154

Payment of business combination contingent consideration

     (8,460     —    

Impairment of cost-method investments

     588       750  

Changes in operating assets and liabilities, net of effect of acquisitions:

    

Accounts receivable, net

     (32,793     2,798  

Inventories, net

     (38,146     26,012  

Prepaid expenses, net deferred income taxes and other current assets

     (28,554     99  

Accounts payable, accrued expenses and other

     12,105       8,764  
  

 

 

   

 

 

 

Net cash provided by operating activities

     273,740       404,973  
  

 

 

   

 

 

 

Cash flows from investing activities:

    

Purchases of property, plant and equipment

     (43,857     (44,133

Patent registration costs

     (6,980     (6,891

Business acquisitions, net of cash acquired

     (3,394     (242,645

Investments in cost-method investments

     (6,464     (8,215

Proceeds / (Payments) on maturity of foreign currency contracts

     10,085       (5,711
  

 

 

   

 

 

 

Net cash used in investing activities

     (50,610     (307,595
  

 

 

   

 

 

 

Cash flows from financing activities:

    

Proceeds from issuance of common stock, net

     15,255       16,937  

Purchases of treasury stock

     —         (102,058

Payment of business combination contingent consideration

     (11,682     (1,228

Proceeds from borrowings, net of borrowing costs

     350,000       310,000  

Repayment of borrowings

     (355,000     (193,092

Dividends paid

     (139,546     (126,026
  

 

 

   

 

 

 

Net cash (used in) / provided by financing activities

     (140,973     (95,467
  

 

 

   

 

 

 

Effect of exchange rate changes on cash

     13,719       (665
  

 

 

   

 

 

 

Net increase / (decrease) in cash and cash equivalents

     95,876       1,246  

Cash and cash equivalents at beginning of period

     731,434       717,249  
  

 

 

   

 

 

 

Cash and cash equivalents at end of period

   $ 827,310     $ 718,495  
  

 

 

   

 

 

 

- More -


Reconciliation of Non-GAAP Financial Measures (Unaudited)

(In US$ thousands, except share and per share data)

The measure, “non-GAAP income from operations” is reconciled with GAAP income from operations below:

 

     Three Months Ended
March 31
     Nine Months Ended
March 31,
 
     2017      2016      2017      2016  

GAAP income from operations

   $ 107,397      $ 104,312      $ 298,437      $ 310,315  

SERVE-HF accrual release (A)

     —          —          —          (2,402

Astral battery field safety notification expenses (A)

     —          —          5,070        —    

Restructuring expenses (A)

     7,945        —          12,358        6,914  

Litigation settlement expenses (A)

     —          —          8,500        —    

Acquisition related expenses (A)

     —          3,550        10,076        3,550  

Amortization of acquired intangible assets (A)

     11,378        4,558        34,809        11,294  
  

 

 

    

 

 

    

 

 

    

 

 

 

Non-GAAP income from operations

   $ 126,720      $ 112,420      $ 369,250      $ 329,671  
  

 

 

    

 

 

    

 

 

    

 

 

 

The measures “non-GAAP net income” and “non-GAAP diluted earnings per share” are reconciled with GAAP net income and GAAP diluted earnings per share in the table below:

 

     Three Months Ended
March 31,
     Nine Months Ended
March 31,
 
     2017      2016      2017      2016  

GAAP net income

   $ 87,823      $ 90,791      $ 240,672      $ 269,283  

SERVE-HF accrual release, net of tax (A)

     —          —          —          (1,682

Astral battery field safety notification expenses (A)

     —          —          3,549        —    

Restructuring expenses, net of tax (A)

     5,210        —          8,295        5,204  

Litigation settlement expenses, net of tax (A)

     —          —          5,392        —    

Acquisition related expenses (A)

     —          3,550        10,076        3,550  

Amortization of acquired intangible assets, net of tax (A)

     7,704        3,416        23,679        8,572  
  

 

 

    

 

 

    

 

 

    

 

 

 

Non-GAAP net income (A)

   $ 100,737      $ 97,757      $ 291,663      $ 284,927  
  

 

 

    

 

 

    

 

 

    

 

 

 

Diluted shares outstanding

     142,724        141,232        142,363        141,666  
  

 

 

    

 

 

    

 

 

    

 

 

 

GAAP diluted earnings per share

   $ 0.62      $ 0.64      $ 1.69      $ 1.90  
  

 

 

    

 

 

    

 

 

    

 

 

 

Non-GAAP diluted earnings per share (A)

   $ 0.71      $ 0.69      $ 2.05      $ 2.01  
  

 

 

    

 

 

    

 

 

    

 

 

 

 

(A) ResMed adjusts for the impact of the Astral battery field safety notification expenses, release of SERVE-HF accrual, restructuring expenses, litigation settlement expenses, acquisition related expenses and amortization of acquired intangible assets from their evaluation of ongoing operations and believes investors benefit from adjusting these items to facilitate a more meaningful evaluation of current operating performance.

ResMed believes that non-GAAP diluted earnings per share is an additional measure of performance investors can use to compare operating results between reporting periods. ResMed uses non-GAAP information internally in planning, forecasting, and evaluating the results of operations in the current period and in comparing it to past periods. ResMed believes this information provides investors better insight in evaluating ResMed’s performance from core operations and provides consistent financial reporting. Our use of non-GAAP measures is intended to supplement, and not to replace, our presentation of net income and other GAAP measures. Like all non-GAAP measures, non-GAAP earnings are subject to inherent limitations because they do not include all the expenses that must be included under GAAP.

- End -